New anticancer agents: in vitro and in vivo evaluation.
The rapid emergence of new anticancer agents is a tremendous challenge for basic, pre-clinical and clinical research to evaluate and eventually integrate these new agents into clinical routine. Standardized, well-established in vitro and in vivo methods are available for the experimental evaluation of new anticancer agents. A step-wise procedure from in vitro to in vivo experiments using non-functional, functional non-clonogenic and, if applicable, clonogenic assays allows reduction of the number of promising agents for further clinical testing.
Zips
Daniel
D
Department of Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany.
Thames
Howard D
HD
Baumann
Michael
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005069:Evaluation Studies as Topic; D006801:Humans; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay / Q000379:methods*
D000970:Antineoplastic Agents